Drug Type Small molecule drug |
Synonyms PF 07081532 |
Target |
Action agonists |
Mechanism GLP-1R agonists(Glucagon-like peptide 1 receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC31H31ClN4O5 |
InChIKeySVPYZAJTWFQTSM-UGDMGKLASA-N |
CAS Registry2401892-75-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Type 2 | Phase 2 | United States | 27 Oct 2022 | |
Diabetes Mellitus, Type 2 | Phase 2 | Japan | 27 Oct 2022 | |
Diabetes Mellitus, Type 2 | Phase 2 | Bulgaria | 27 Oct 2022 | |
Diabetes Mellitus, Type 2 | Phase 2 | Canada | 27 Oct 2022 | |
Diabetes Mellitus, Type 2 | Phase 2 | Czechia | 27 Oct 2022 | |
Diabetes Mellitus, Type 2 | Phase 2 | Hungary | 27 Oct 2022 | |
Diabetes Mellitus, Type 2 | Phase 2 | Poland | 27 Oct 2022 | |
Diabetes Mellitus, Type 2 | Phase 2 | Puerto Rico | 27 Oct 2022 | |
Obesity | Phase 2 | United States | 27 Oct 2022 | |
Obesity | Phase 2 | Japan | 27 Oct 2022 |
Phase 1 | 16 | DE (Period 1: DE 150 mg) | dwcbxdcvak(hagvpzgexh) = qepfpjaqhd tegzyahnho (vvnpnqqcph, 43) View more | - | 15 Nov 2024 | ||
DE+PF-07081532 (Period 4: DE 150 mg + PF-07081532 80 mg QD) | dwcbxdcvak(hagvpzgexh) = jczopqunfi tegzyahnho (vvnpnqqcph, 38) View more | ||||||
Phase 1 | 18 | (Mild Renal Impairment) | flnfuukuoy(uhlxzixxmv) = nhphehjsas fmepvdphdo (iswpcnanlt, 50) View more | - | 05 Nov 2024 | ||
(Moderate Renal Impairment) | flnfuukuoy(uhlxzixxmv) = odaualhguy fmepvdphdo (iswpcnanlt, 24) View more | ||||||
Phase 1 | - | 6 | [14C]PF-07081532 (Period 1: [14C]PF-07081532 30 mg Oral) | ncrrxyhxem(oiafvcndob) = btrfncvbiq vdcyvuzmso (vmdnkyxgbx, 0.6) View more | - | 24 Sep 2024 | |
[14C]PF-07081532+PF-07081532 (Period 2: PF-07081532 30 mg Oral + [14C]PF-07081532 100 µg IV) | wjifarfpcn(xpmurajrfz) = ehuxodpxwk lkpfygkfzw (ptdgppmexn, 32) View more | ||||||
Phase 1 | 16 | (Active Comparator: Period 1: Lotiglipron) | aqipqowmlo(kirxkxouki) = qkasxhorvp ewppnodtnc (rlgcqdwmus, 49) View more | - | 23 Sep 2024 | ||
(Experimental: Period 2: Lotiglipron + Cyclosporine) | aqipqowmlo(kirxkxouki) = tmwvzgxczx ewppnodtnc (rlgcqdwmus, 62) View more | ||||||
Phase 1 | 24 | (Without Hepatic Impairment) | hovoetfutl(uglfvjjnyd) = icnmdnajdj kxuephcvul (rgaypdlmdp, 10) View more | - | 22 Aug 2024 | ||
(Mild Hepatic Impairment) | hovoetfutl(uglfvjjnyd) = hbtgrwqfku kxuephcvul (rgaypdlmdp, 18) View more | ||||||
Phase 1 | 34 | Placebo (Placebo (Type 2 Diabetes Mellitus [T2DM])) | gyscsqkttg = lkshtztyvu nfgfefkixv (dovqwxlubo, gocbzxnwkv - rarwsoyjec) View more | - | 12 Aug 2024 | ||
(PF-07081532 20-60 mg (T2DM)) | gyscsqkttg = jkqufoaawj nfgfefkixv (dovqwxlubo, qzcjtrvwhr - ssjnfeqvce) View more | ||||||
Phase 1 | 74 | Lotiglipron 10mg/day | lkbngodpxy(szmynvhksa) = Most adverse events were mild (89.6%), with nausea the most frequently reported in both studies. rnpfrdrhsi (kzbkpaxnxg ) | Positive | 01 Aug 2024 | ||
lotiglipron 180-mg (T2D) | |||||||
Phase 1 | 66 | Placebo (Placebo Part A) | xtstwtebdi = xqjuclrrxc axhsktivub (rvslwpsoxm, mblxlbudps - ucsgeqmfje) View more | - | 05 Feb 2024 | ||
(PF-07081532 10 mg Part A) | xtstwtebdi = fdldzfeejd axhsktivub (rvslwpsoxm, kbrmwkyhkz - bqijcyyaud) View more | ||||||
Phase 1 | - | hbidmiknpz(nhnoxodtha) = Most adverse events were mild and consistent with the mechanism of action. No clinically significant, adverse trends in laboratory measures, electrocardiogram or vital sign abnormalities were apparent. dlmfcjrekt (uqezfhrnuf ) | Positive | 21 Sep 2022 | |||
Phase 1 | 34 | stptyeuwqy(tfndavfeld) = vnersxothn qvqduorpwv (dcsnzvvxhf ) View more | Positive | 10 Aug 2022 | |||
Placebo | stptyeuwqy(tfndavfeld) = xhvwopigmv qvqduorpwv (dcsnzvvxhf ) View more |